文献速递流行病学与生物统计临床试验与 GCP

内分泌与代谢疾病靶向治疗临床试验注册与发表实践不佳:一项观察性研究

Poor registration and publication practices in clinical trials of targeted therapeutics for endocrine and metabolic diseases: an observational study.
PubMed 文献 · J Clin Epidemiol · 2024-10-16

该观察性研究于2022年9月检索临床试验注册库,纳入2005年起注册的内分泌与代谢疾病靶向治疗已完成的干预性试验,评估注册信息完整性与发表文章的一致性。149项试验中121项(81%)有对应发表文章;89项(67%)初始注册缺失强制条目,17项(13%)最终更新缺失,85项(77%)发表文章缺失。所有试验初始注册与最终更新间均有变化,98%从初始注册到发表有变化。

要点

  • 149项试验中121项(81%)有对应发表文章
  • 89项(67%)初始注册缺失强制数据条目,85项(77%)发表文章缺失
  • 所有试验注册信息在初始与最终更新间均有变化,98%从注册到发表有变化

核心结论

  • 尽管存在法律和期刊注册要求,内分泌与代谢疾病靶向治疗试验在注册库和对应发表文章中强制数据条目的完整性和一致性不足。
  • 研究结果对靶向治疗临床试验的诚信和可靠性提出疑问。

研究设计与样本

  • 观察性研究,于2022年9月检索临床试验注册库,纳入2005年起注册的内分泌与代谢疾病靶向治疗已完成的干预性试验。
  • 依据ClinicalTrials.gov和世界卫生组织国际临床试验注册平台的注册要求提取数据,评估初始注册与最终更新的完整性及与发表文章的一致性。
  • 共纳入149项临床试验。

主要发现

  • 149项试验中121项(81%)有对应发表文章。
  • 89项(67%)试验在初始注册时缺失强制注册数据条目,17项(13%)在最终注册更新时缺失,85项(77%)对应发表文章缺失。
  • 所有试验在初始注册与最终注册更新之间均显示变化,98%从初始注册到发表显示变化。
  • 初始注册与最终更新间变化最常见的类别为「完成日期」(92%)、「关键次要结局」(82%)和「首例入组日期」(70%)。
  • 初始注册与发表间变化最常见的类别为「样本量」(91%)、「关键纳入和排除标准」(81%)、「关键次要结局」(84%)和「完成日期」(83%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the completeness and concordance of reporting in registries and corresponding publications of interventional trials on targeted therapeutics for endocrine and metabolic disorders. STUDY DESIGN AND SETTING: We searched clinical trial registries in September 2022 for completed interventional trials of target therapeutics for endocrine and metabolic disorders registered from 2005 onwards. We used ClinicalTrials.gov and the World Health Organization International Clinical Trial Registration Platform registration requirements to extract data and assess the completeness of initial entry and final updates to trial registration and concordance with their published journal articles. RESULTS: Among 149 clinical trials included, 121 (81%) had corresponding publications. Missing mandatory registration data items were identified in 89 (67%) trials at the initial registration entry, 17 (13%) at the final registration update, and in 85 (77%) corresponding publications. All trials showed changes between initial registration entry and final registration update, and 98% showed changes from the initial registration entry to publication. Changes between initial registration entry and final registration update were most common in the categories 'Completion date' (92%), 'Key secondary outcomes' (82%), and 'Date of first enrolment' (70%). Changes between initial registration entry and publication were most common in categories 'Sample size' (91%), 'Key inclusion and exclusion criteria' (81%), 'Key secondary outcomes' (84%), and 'Completion date' (83%). CONCLUSION: Despite the legal and journal registration requirements, the completeness and consistency of reporting mandatory data items in registries and corresponding publications regarding targeted therapeutics for endocrine and metabolic disorders are inadequate. Our findings raise questions about the integrity and reliability of clinical trials focusing on targeted therapeutics. PLAIN LANGUAGE SUMMARY: This study evaluated the completeness of reporting of mandatory information about clinical trials of targeted therapies for endocrine and metabolic diseases in trial registries and published articles. Furthermore, we examined whether the information in trial registries aligns with what is reported in scientific journals. Our analysis focused on completed interventional trials registered from 2005 onwards using trial registries. We found that 67% of the included trials were missing mandatory information at the time of initial entry into registry, while 77% of the matching publications also lacked mandatory information. The most common discrepancies between the entry into registry and published data occurred in the mandatory categories of sample sizes and key inclusion and exclusion criteria for participants. Our findings highlight major gaps in how clinical trials for targeted therapies in endocrine and metabolic diseases are conducted. Despite established requirements for accurate registration and publication of mandatory trial information, substantial discrepancies persist between the data in registries and published results. These inconsistencies raise concerns about the reliability of reported findings and underscore the urgent need for improved practices in trial registration and reporting.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Pavić M, Tokalić R, Marušić A, et al. Poor registration and publication practices in clinical trials of targeted therapeutics for endocrine and metabolic diseases: an observational study. J Clin Epidemiol. 2024. PMID: 39419357. doi:10.1016/j.jclinepi.2024.111570

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。